Upregulation of the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 and subsequent cell growth arrest or senescence is one mechanism by which normal cells are believed to respond to stress induced by the constitutively activated GTPase Ras. We hypothesize that in the absence of p21, the onset of Ras-dependent oncogenesis is accelerated. To test this hypothesis, we crossed MMTV/v-Ha-ras transgenic mice into a p21-de®cient background. By 63 days of age, all 8 ras/p21 7/7 mice developed either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors. In contrast, by the same age, only one out of nine of the ras/p21 +/+ mice developed a tumor. Furthermore, by 94 days of age, half of the ras/p21
Upregulation of the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 and subsequent cell growth arrest or senescence is one mechanism by which normal cells are believed to respond to stress induced by the constitutively activated GTPase Ras. We hypothesize that in the absence of p21, the onset of Ras-dependent oncogenesis is accelerated. To test this hypothesis, we crossed MMTV/v-Ha-ras transgenic mice into a p21-de®cient background. By 63 days of age, all 8 ras/p21 7/7 mice developed either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors. In contrast, by the same age, only one out of nine of the ras/p21 +/+ mice developed a tumor. Furthermore, by 94 days of age, half of the ras/p21 7/7 mice, but none of the ras/p21 +/+ mice, developed mammary tumors. p21-de®ciency also accelerated the development of salivary (T 50 =66 days for ras/p21 7/7 vs T 50 =136 days for ras/p21 +/+ ) and Harderian (T 50 =52 days for ras/p21 7/7 vs T 50 4221 days for ras/p21 +/+ ) tumors. Furthermore, two out of the eight ras/p21 7/7 mice had metastatic lesions, one in its lungs, the other in its abdomen. None of the nine ras/p21 +/+ mice had metastatic lesions. By 4 months of age, the mammary tumor multiplicity was 10-fold greater in ras/p21
Introduction
The ras oncogenes are frequently activated by point mutations or overexpression in human tumors (Barbacid, 1990; Bos, 1989) . About 30% of all human tumors are associated with ras mutations and up to 95% of human pancreatic cancers contain K-ras mutations (Barbacid, 1990; Bos, 1989) . Ras proteins are believed to mediate their oncogenic eect, in part, by dysregulating the cell cycle machinery (Downward, 1997; Ewen, 2000; Kerkho and Rapp, 1998) . For instance, activated Ras, acting through the Raf/Mek/ Erk kinase pathway, was shown to increase cyclin D1 expression and to shorten the G1 phase of the cell cycle (Aktas et al., 1997; Arber et al., 1996; Filmus et al., 1994; Hitomi and Stacey, 1999; Liu et al., 1995; Peeper et al., 1997; Robles et al., 1998; Winston et al., 1996) . Moreover, Raf kinase was shown to interact with and regulate the activity of cdc25A, a phosphatase involved in the regulation of cdc2, an essential G2/M kinase (Xia et al., 1999) . Unlike NIH3T3 cells, which have lost cyclin dependent kinase inhibitors (CKI) such as p16 or p19, activated Ras alone does not transform primary murine ®broblasts, but requires a cooperating oncogene (Franza et al., 1986; Hirakawa and Ruley, 1988; Parada et al., 1984; Yancopoulos et al., 1985) . Interestingly, by itself, activated Ras causes growth arrest in these cells. From recent work, it is now apparent that this growth inhibitory eect of a strong Ras signal is due to the ability of the Raf/Mek/Erk pathway to induce expression of the CKI p21 WAF1/CIP1 (hereafter referred to as p21) . A strong indication that the cell cycle arrest induced by a high intensity Ras/Raf signal is mediated by a high p21 level comes from the observation that in p21-de®cient ®broblasts these signals do not lead to cell cycle arrest (Olson et al., 1998) . Furthermore, inhibition of p21 expression with antisense oligonucleotides relieved Rasmediated growth arrest (Delgado et al., 2000) .
Altogether, these studies point to p21 as being one of the targets of the Ras/Raf signaling pathway. It is possible that the apparent ability of oncogenic Ras or Raf to induce the expression of p21 is a protective or stress response of the cell to receiving a strong Ras/Raf signal at an inappropriate stage in the cell cycle. Hence, loss of p21 could release the cell from the cell cycle arrest caused by a strong Ras signal.
p21 is induced in response to a broad spectrum of cellular stresses, thus allowing the cell to halt cell cycle progression (Gartel et al., 1996) . One critical cellular stress is DNA damage, after which p53-mediated p21 induction has been shown to play an important role in the cellular response (Dulic et al., 1994; Macleod et al., 1995; Namba et al., 1995) . In addition, several studies have implicated p21 in both p53-mediated G1 arrest and apoptosis (Polyak et al., 1996; Wagner et al., 1994; Waldman et al., 1995) . In normal human cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating cell nuclear antigen (PCNA), a processivity factor of DNA polymerase d (Zhang et al., 1993) . p21 modulates CDK activity, thereby aecting cell cycle progression, whereas its eect on PCNA may be important in DNA replication and/or excision repair.
Investigation of naturally arising tumors has indicated that unlike p16, deletion or mutation of the p21 gene is not common in human tumors and is not a probable mechanism of inactivation of this gene (Balbin et al., 1996; Gao et al., 1995; Shiohara et al., 1994; Terry et al., 1996) . The involvement of p21 in tumor suppression has also been questioned, as mice lacking p21 undergo a normal development, harbor no gross alterations in their organs, and exhibit no increase in spontaneous tumor development (Brugarolas et al., 1995; Deng et al., 1995) . However, even in p53-de®cient mice, spontaneous tumor formation occurred only in a few tissues (Jacks et al., 1994) . Thus, it is possible that in speci®c tissues or cell types, p21 may exert a tumorsuppressing function, which would be unmasked under conditions where other genetic alterations are present. Recent studies have shown that loss of p21 aects tumor progression negatively or positively depending upon the nature of the oncogenic stimuli (Jones et al., 1999; Missero et al., 1996; Wang et al., 1997) . For example, ATM-de®cient mice exhibited a retarded tumor development in the absence of p21 (Wang et al., 1997 ). Yet, heterozygosity for p21 was shown to enhance tumor cell proliferation and cyclinD1-associated kinase activity in Wnt-1 transgenic mice (Jones et al., 1999) . Furthermore, p21-null keratinocytes that were transformed with an activated ras exhibited a more aggressive tumorigenic behavior in nude mice than did those of their p21-wild type counterparts (Missero et al., 1996) . However, a similar study failed to show an eect of p21 on tumors formed by ras-transformed keratinocytes (Weinberg et al., 1997) . Finally, a role for p21 in a mouse skin carcinogenesis model is also controversial, as one study showed an increase in papilloma formation associated with the loss of p21 , while another found no signi®cant changes in regard to tumor initiation, conversion or progression between p21-null mice and their p21-wild type counterparts (Philipp et al., 1999) . However, this same study found that the carcinomas arising from the p21 7/7 mice were more poorly dierentiated. Yet, a third study (Topley et al., 1999) demonstrated that chemical carcinogenesis of p21 7/7 mice resulted in multiple skin carcinoma formation.
In this study, we crossed p2l-de®cient mice (Brugarolas et al., 1995) with tumor-susceptible MMTV/v-Haras transgenic mice (Sinn et al., 1987) and demonstrated that p2l-de®ciency dramatically accelerates the onset and increases the multiplicity and aggressiveness of Ras-dependent tumors.
Results

p21-deficiency cooperates with v-Ha-Ras to accelerate tumor onset
To evaluate the consequences of p2l de®ciency in the context of Ras-mediated tumorigenesis, we crossed female mammary tumor susceptible MMTV/v-Ha-ras transgenic mice with male p2l knockout mice. The MMTV promoter sequence controls the expression of the fused v-Ha-Ras oncogene, which contains activating mutations in codons 12 (Gly to Arg) and 59 (Ala to Thr). The MMTV/v-Ha-ras mice are highly susceptible to proliferative disturbances of the mammary, salivary, and lymphoid tissues (Sinn et al., 1987) , while heterozygous and p21 knockout mice develop normally (Brugarolas et al., 1995; Deng et al., 1995) . At the second generation, we obtained ospring of the various genotypes that harbored the ras transgene and dierent dosages of p2l in a Mendelian ratio [ras/p21 7/7 (eight mice), ras/p21
(17 mice) and ras/p21 +/+ (nine mice)]. Mice from the same genetic background harboring dierent dosages of p2l, but lacking the ras transgene, were kept as controls. All mice were monitored weekly for tumors by palpation. Noncarrier ras control siblings (n=9) did not develop tumors during the observation period. In this study, females were used exclusively. Histologic examination of the salivary and mammary tumors consistently revealed the presence of adenocarcinomas of the salivary and mammary tissue (see below). When tumors were detected, their diameters were measured in three dimensions and measured again at 1-week intervals until sacri®cing of an animal was warranted due to the animal's tumor burden.
To determine whether p21 functional status could in¯uence tumor onset, the ras/p21 7/7 group of mice was compared with that of the ras/p21 +/7 and the ras/ p21 +/+ mice. We ®rst analysed the data in terms of all tumors combined: malignant (mammary or salivary adenocarcinomas) and benign (Harderian gland hyperplasia). All the ras/p21 7/7 mice (8/8) developed tumors within 63 days of age. Half of these mice (4/8) developed tumors by age 52 (T 50 =52 days) ( Figure  1a ). In contrast, the ras/p21 +/+ mice (n=9) developed tumors at a later age (T 50 =120 days) (P=0.0004). However, compared with the ras/p21 7/7 and the ras/ p21 +/+ mice, the ras/p21 +/7 mice (n=17) developed tumors at an intermediate age (T 50 =78 days) (P=0.0218 and P=0.0977, respectively). Furthermore, by 221 days of age, 22% of the ras/p21 +/+ mice were still tumor free whereas none of the ras/p21 7/7 mice were tumor free by the age of 63 days ( Figure 1A ).
We next evaluated the eect of p21 loss on the onset of each tumor type separately. Figure 1B shows that by 63 days of age, 100% of ras/p21 7/7 mice (n=8) had Harderian gland hyperplasia whereas, only 11 and 41% of ras/p21 +/+ (n=9) and ras/p21 +/7 (n=17) mice did, respectively. Thus, p21-de®ciency enhanced Harderian gland hyperplasia by 10-fold [P=0.0168 (+/7 vs 7/ 7); P=0.0003 (+/+ vs 7/7); P=0.0509 (+/+ vs +/7)]. Figure 1C shows that half of the ras/p21 7/7 mice developed salivary tumors by age 66 days, in contrast to ras/p21 +/+ and ras/p21 +/7 mice which had T 50 values of 136 and greater than 221 days of age, respectively [P=0.0001 (+/7 vs 7/7); P=0.075 (+/ + vs 7/7); P=0.3878 (+/+ vs +/7)]. Similarly, Figure 1D shows that the ras/p21 7/7 mice had a much shorter T 50 than the ras/p21 +/+ and the ras/p21
mice (94, 136 and 154 days, respectively) for mammary tumor development [P=0.0001(+/7 vs 7/7); P=0.0009(+/+ vs 7/7); P=0.5557(+/+ vs +/7)].
In the ras/p21 7/7 mice, salivary tumors appeared ®rst, followed by mammary tumors (T 50 =66 days vs T 50 =94 days) (Hazard Ratio=0.50, P=0.327). The hazard ratio is the ratio of the hazard of developing the ®rst tumor to the hazard of developing the second at any time. For example, for the ras/p21 7/7 mice, the hazard ratio of 0.50 for mammary : salivary means that these mice had about 50% greater hazard of developing salivary tumors than mammary tumors. In contrast, in ras/p21 +/+ mice, the T 50 =136 was the same for both mammary and salivary tumors. Moreover, a subcutaneous malignant vascular tumor of high grade, which expressed high levels of factor VIII, consistent with angiosarcoma, was identi®ed in 1 out of 8 ras/p21 7/7 mice examined (data not shown). Finally, at autopsy, we found that two out of eight ras/p21 7/7 mice and one out of 17 ras/p21 +/7 mice had metastatic mammary tumors visible on the surface of the lungs or in the abdomen ( Figure 4E ). In contrast, none of the ras/p21 +/+ mice (n=9) had developed tumor metastases (P=0.1932). Altogether, these results show that tumor onset and incidence in MMTV/v-Ha-ras mice were p2l-dependent with loss of p2l associated with an earlier tumor onset and increased tumor burden. Although there was an increase in metastasis in ras/p21 7/7 mice, this was not statistically signi®cant and more animals are required to determine whether or not loss of p21 is important for metastasis.
The most frequent abnormality detected was a bilateral hyperplasia of the Harderian lacrimal glands. By age 63 days, eight out of eight ras/p21 7/7 (100%), seven out of 17 ras/p21 +/7 (41%) and one out of nine ras/p21 +/+ (11%) mice had hyperplasia (7/7 vs +/+, P=0.0003; 7/7 vs +/7, P=0.0168; +/7 vs +/+ P=0.0509) ( Figure 1B ). The Harderian gland is a tubulo-alveolar gland found within the orbit on the posterior aspect of the eyeball. Enlargement of the glands in ras/p21 7/7 mice was evident as early as 5 Figure 1 Tumor incidence in female MMTV/v-Ha-ras transgenic mice of dierent p21 genotypic backgrounds. Mice were monitored for tumors on a weekly basis by both observation and palpation. The age in days was recorded at the time of ®rst observation of a tumor. The T 50 (age by which half of the mice developed tumors) for all tumors combined was 52 days for ras/ p21 7/7 (n=8), 78 days for ras/p21 +/7 (n=17), and 120 days for ras/p21 +/+ (n=9) mice. (A) shows the incidence of all tumors combined, (B) the incidence of Harderian gland hyperplasia, (C) the incidence of salivary tumors, and (D) the incidence of mammary tumors. The graphs are not based on Kaplan-Meier estimations. Rather, they represent actual tumor occurrence in the samples weeks after birth, with glands reaching up to 20 times their normal weight (average of 296.4+91.6 mg in hyperplastic glands vs 18.4+1.5 mg in normal glands) by the age of 4 months.
Histological examination of the tissue revealed a glandular hyperplasia with no evidence of focal or malignant tumors. It has been shown previously that neu, mos and ret transgenes can also induce Harderian gland hyperplasia, thus revealing an unusual response by this organ to various classes of oncogenes (Heath et al., 1992; Lucchini et al., 1992; Sinn et al., 1987) .
Tumor growth rate and multiplicity
The data described in Figure 1 demonstrate that lack of p21 dramatically accelerates the onset of Ras-dependent tumorigenesis. To determine if p21-de®ciency also aects the growth rate of tumors, the size of tumors was measured over time in the three dierent genetic backgrounds. The graphs in Figure 2 show the tumor growth rate of salivary (panel A) and mammary (panel B) tumors for each group, ras/p21
, ras/p21
, and ras/p21 +/+ during a 4-week time period from the ®rst day of tumor appearance. Although the salivary tumors of the ras/p21 7/7 mice grew at a somewhat faster rate than those of the ras/p21 +/+ mice, the dierence is not statistically signi®cant. A similar ®nding was obtained when the growth rate of mammary tumors of ras/p21 7/7 mice was compared with that of ras/p21 +/+ mice. Thus, the growth rate of the mammary and salivary tumors was independent of p21 functional status.
Next, we evaluated the eect of p21-de®ciency on the number of tumors developed per mouse (Figure 3) . Although the tumor growth rate was not p21-dependent, the multiplicity of tumors was highly dependent on p21 dosage. Figure 3 shows that, by the age of 115 days, the ras/p21 7/7 mice harbored multiple mammary tumors averaging 3.4 tumors per mouse. In contrast, the ras/p21 +/7 and ras/p21 +/+ mice harbored an average of 0.35 and 0.33 mammary tumors per mouse, respectively (P50.0001 and P=0.0004) ( Figure 2B) . Furthermore, at the time of sacri®ce, the average number of mammary tumors per mouse was 3.75, 2.11 and 1.33 for ras/p21
, ras/p21 +/ 7 and ras/p21
, respectively. These results show that, although the tumor growth rate was independent of p21 functional status, the p21-de®cient mice more frequently developed multiple tumors than did the p21-heterozygous or p21-wild type mice.
Histopathology
The tumors, across the three genotypes, had a disorganized appearance with densely packed neoplastic cells with high mitotic and proliferation indices ( Figure 4A ± D) . Little or no normal tissue remained and areas of necrosis were common. There was a moderate in¯ammatory response in all of the mice, as evidenced by lymphocytic in®ltration of tumor tissues. Moreover, ras/p21 7/7 and ras/p21 +/7 mice developed mammary adenocarcinomas of ductal type with higher nuclear grade than ras/p21 +/+ mice ( Figure 4A,B) . The mice, across the three genotypes, developed adenocarcinomas of the salivary gland of acinar type ( Figure  4C,D) . Furthermore, ras/p21 7/7 mice developed sple- Figure 2 Salivary and mammary tumor growth rate in ras/p21 7/ 7 , ras/p21 +/7 and ras/p21 +/+ mice. After the ®rst observation of a mammary or salivary tumor, tumor size was measured weekly thereafter, and tumor volumes were calculated as previously described by Miller et al. (1988) . Time`1' represents the ®rst day at which the tumor was observed, and Times`2' to`4' represent weekly subsequent measures of tumor volume. , ras/p21 +/7 and ras/ p21 +/+ mice. The number of mammary tumors developed in each ras/p21 group of mice by the age of 4 months was plotted. ras/ p21 7/7 mice harbored 3.4 mammary tumors per mouse, while the ras/p21 +/7 and ras/p21 +/+ mice harbored an average of 0.35 and 0.33 mammary tumors per mouse Oncogene p21 WAF1/CIP1 loss accelerates Ras oncogenesis J Adnane et al nomegaly ( Figure 5A ). The spleens from ras/p21
mice had average lengths of 3.3+0.7 cm, whereas ras/ p21 +/+ mice had an average of 1.5+0.3 cm. Histologically, the splenomegaly was due to a moderate to marked extramedullary hematopoiesis, frequently displaying atypical lymphoid cells and megakariocytes ( Figure 5B ). In the spleen, the labeling index with Ki-67 was 2.5-fold higher in ras/p21 7/7 than in ras/p21 +/+ mice (average of 55.6+10.2% vs 21.1+7.7%). However, the overall level of apoptotic cells in the spleen was similar across the three genotypes. This is consistent with the work of Balomenos et al which shows that T-lymphocytes from p21 7/7 mice had an increased proliferation rate after in vitro IL-2 stimulation (Balomenos et al., 2000) . Cheng et al. (2000) also showed that p21 7/7 mice have increased hematopoietic stem cell proliferation. Thus, the lack of p21-induced enlargement of the spleen was mostly due to an increase in cell proliferation rather than to a decrease in apoptosis. Representative tissue sections of spleen were stained with antibodies to CD3 and CD20 to characterize the type of proliferating cells present. A higher number of B cells and a smaller T-cell population were found, suggesting a polyclonal cell proliferation ( Figure 5C ,D).
Tumor growth characteristics of MMTV/v-Ha-ras mice deficient in p21
Tumor growth re¯ects a balance between cell proliferation and cell death. The dynamics of this balance were investigated in tumors from each genotypic group. In Figure 4 Histopathology of tumors in ras/p21 mice. Mammary ductal carcinomas in ras/p21 7/7 (A) and ras/p21 +/+ (B) mice. Salivary gland acinic cell carcinomas in ras/p21 7/7 (C) and ras/p21 +/+ (D) mice. Note higher grade, slightly larger, and more hyperchromatic nuclei in tumors of ras/p21 7/7 animals (A and C). (E,F) Low-power view (E) and Ki-67 immunostaining (F) of lung parenchyma with metastatic mammary ductal carcinoma. Tumor cells exhibit markedly higher proliferation, as shown by immunoreactive brown nuclei, than surrounding normal bronchial epithelium (F, arrow). A-D, 6500; E, 650 (hematoxylin-eosin). F, 6500 (immunoperoxidase) situ labeling of apoptotic cells was accomplished by the TUNEL method and positively stained cells were evaluated by light microscopy, as described in Materials and methods. In both the ras/p21 +/+ and ras/p21 (1.5+0.8%). However, the dierence in apoptosis between the ras/p21
and ras/p21 7/7 mice was not statistically signi®cant (P=0.333). Thus, loss of p21 does not seem to alter the apoptotic characteristics of the Ras-mediated salivary tumors.
To assess tumor cell proliferation, two assays were used: mitotic ®gure counts and Ki-67 staining. The mitotic ®gure assay provides an estimate of the percentage of cells in a tumor undergoing division at one particular time. Mitotic ®gure counts were performed on H&E-stained tumor sections as described in Materials and methods. The ras/ p21 p21 expression is decreased in advanced ras/p21
To determine the status of p21 expression in tumors developed by ras/p21 +/+ mice, the paran-embedded tumor tissue was analysed by immunohistochemistry with an anti-p21 antibody. In tumor tissue from two ras/p21 +/+ mice, p21 expression was absent in the nuclei of tumor cells, but present in the nuclei of adjacent stromal tissue (data not shown). However, p21 expression was unaltered in normal spleen and lung tissue collected from the same ras/ p21 +/+ mice (data not shown). Although our data suggest that p21 expression may need to be suppressed for initiation of Ras tumorigenesis, quantitative determination of the level of p21 expression in tumors arising in ras/p21 +/+ and ras/ p21 +/7 needs to be assessed to con®rm this suggestion.
Discussion
Normal cells, challenged with stresses such as genetic insults, trigger a variety of intracellular programs that lead to either cell growth arrest, senescence, or apoptosis. One of the major mechanisms involved in these stress responses is induction of the cyclin dependent kinase inhibitor, p21. For example, constitutively activated Ras was shown to induce cell growth arrest or senescence, and this has been attributed, in part, to p21 induction (Olson et al., 1998; Sewing et al., 1997; Woods et al., 1997) . The induction of p21 by activated Ras could represent a mechanism by which a cell facing a permanent active Ras signal avoids initiation of oncogenesis. This observation supports the notion that a single oncogene is insucient for cell transformation and that additional changes involving oncogenes and/or tumor suppressor genes are necessary to achieve a fully malignant phenotype. We and others have shown that the Ras-related GTPase RhoA suppresses p21 induction, which provides a potential mechanism by which Ras and RhoA cooperate to induce cell transformation (Adnane et al., 1998; Olson et al., 1998) . The hypothesis upon which the present work is based is that in the absence of p21, activated Ras signaling would have no eective downstream block and tumor initiation and/or progression would be augmented. This hypothesis was tested previously but with con¯icting results. For example, Missero et al. (1996) have shown that ras transformed p21-null primary keratinocytes were highly aggressive compared to their p21-wild type counterparts when injected subcutaneously into nude mice. However, a similar study, in which p21-null keratinocytes were transduced with a vHa-ras-retrovirus and grafted onto nude mice, failed to show an eect of p21 on malignant progression (Weinberg et al., 1997) . In the present report, the model used, in contrast with the xenograft approach, allowed the discrimination of tumor multiplicity and preserved stromal in¯uences in the tumor's own microenvironment.
We have crossed MMTV/v-Ha-ras transgenic mice into a p21-de®cient background to evaluate the in vivo function of p21 in the context of Ras oncogenesis. The long terminal repeat (LTR) of the mouse mammary tumor virus (MMTV) has proved to be an extremely useful tool to direct expression of a number of oncogenes and growth factors to the mammary and salivary glands, with consequences ranging from mild hyperplasia to frank adenocarcinoma (Bouchard et al., 1989; Chooi et al., 1994; Daphna-Iken et al., 1998; Iwamoto et al., 1990; Matsui et al., 1990; Ritland et al., 1997; Sinn et al., 1987; Wang et al., 1994; Yao et al., 1999) . The ras transgenic models have demonstrated that mutation of ras genes can be an important factor in oncogenesis (Andres et al., 1987; Efrat et al., 1990; Quaife et al., 1987; Sandgren et al., 1989; Sinn et al., 1987; Suda et al., 1987; Tremblay et al., 1989) . With the exception of the results of Quaife et al. (1987) , Ras oncoprotein, by itself, was not sucient to induce tumorigenesis. Activation of a second oncogene, c-myc or SV40-T antigen, accelerated the onset of transformation, but did not change the overall disease pattern (Andres et al., 1988; Sandgren et al., 1989; Sinn et al., 1987) . In our study, the ospring of the various genotypes harboring the ras transgene with diering dosages of p2l (ras/p2l
, ras/p2l
, ras/p2l +/+ ) were monitored for tumor formation. p21-de®cient mice, carrying the ras transgene, developed tumors in a shorter time (T 50 =52 days) compared with the p21-heterozygous (T 50 =78 days) and p21-wild type (T 50 =120 days) mice. Moreover, by the age of 4 months, ras/p21 7/7 mice developed an average of 3.4 mammary tumors per mouse while ras/p21 +/7 and ras/ p21 +/+ mice developed an average of only 0.35 and 0.33 mammary tumors per mouse. Thus, p21 de®ciency increased tumor multiplicity by 10-fold. This is consistent with experimental mouse skin chemical carcinogenesis studies by Weinberg et al. (1999) where p21-null mice developed more papillomas than did p21-wild type mice. This is also consistent with the work of Topley et al. (1999) which suggested that loss of p21 results in an increased number of targeted cells. In our model, p21-de®ciency accelerated the onset of ras tumors and increased the number of tumors developed per mouse, suggesting that p21-de®ciency can substitute for changes that accelerate Ras-induced tumorigenesis.
While ras/p21 +/+ mice developed mammary tumors or salivary tumors at a similar relatively late age (T 50 =136), ras/p21 7/7 mice tended to develop salivary tumors ®rst (T 50 =66), followed by mammary tumors (T 50 =94). This result suggests that the salivary gland may be more sensitive than the mammary gland to p21-de®ciency. Salivary gland adenocarcinomas were previously observed in models that utilize the mammary speci®c MMTV LTR to control Ras expression (Sinn et al., 1987; Tremblay et al., 1989) , although the incidence of salivary gland neoplasia was usually much lower (0 ± 19%) than the one observed in our ras/p21-null model (75%).
At autopsy, we found that two out of eight ras/p21
and one out of 17 ras/p21 +/7 mice had metastatic mammary tumors on the lungs or abdomen, while no tumor metastases were observed in ras/p21 +/+ mice. Although the results suggest that loss of p2l is associated with an increased aggressiveness of ras tumors, this needs to be con®rmed with a larger population of animals. Our results, however, are in accord with a study by Missero et al. (1996) that showed that ras-transformed p21-null keratinocytes were highly aggressive compared with their p21-wild type counterparts.
It was somewhat surprising to ®nd that the tumor growth rate of ras/p21 7/7 mice was not higher than that of ras/p21 +/+ mice, and that cell death and proliferation levels were similar across the three genotypes. Because loss of p21 and activation of Ras clearly cooperated to accelerate tumor onset, it might have been expected that the tumors would also have increased growth rates, with p21-de®ciency contributing to an elevated rate of proliferation and Ras contributing to the suppression of apoptosis. Ras was shown to inhibit the cellular susceptibility to apoptosis, including spontaneous apoptosis (Arends et al., 1993) , apoptosis induced by irradiation , E1A expression (Lin et al., 1995) , doxorubicin (Nooter et al., 1995) , or cytokine withdrawal (Kinoshita et al., 1995) . The eect on tumor onset and lack of eect on tumor growth rate and apoptosis suggests that p21-de®ciency is critical for early but not late events of oncogenesis.
Furthermore, in the Harderian gland epithelium, in which the v-Ha-ras gene product exerted a nonneoplastic proliferative eect, one can conclude that the loss of p21 did not cooperate with activated Ras to achieve a fully malignant phenotype. This is in agreement with a study that showed that p21-null primary murine ®broblasts were resistant to transforp21 WAF1/CIP1 loss accelerates Ras oncogenesis J Adnane et al mation by oncogenic ras and that additional changes were necessary to achieve a fully transformed phenotype (Pantoja and Serrano, 1999) . To summarize, the ®ndings described in this report demonstrate that the onset and multiplicity of tumors were profoundly dierent, but the overall tumor growth rates were similar across the three genotypes, implicating p21 in suppressing early but not late events of oncogenesis. Furthermore, the ras/p21 transgenic mouse will be a useful and informative model for testing therapies directed against Ras-associated tumorigenesis.
Materials and methods
Mice
Tumor-susceptible MMTV/v-Ha-ras transgenic mice (Sinn et al., 1987) in an inbred FVB/N genetic background were obtained from Charles River Laboratories (Wilmington, MA, USA). p21 WAF1/CIP1 knockout mice (p21
) of mixed 129/Sv and B6 background were kindly provided by Tyler Jacks (Brugarolas et al., 1995) . The generation, biological characterization, and tumor susceptibility of the MMTV/v-Ha-ras and p21
WAF1/CIP1 knockout mice have been described previously (Brugarolas et al., 1995; Sinn et al., 1987) . MMTV/vHa-ras transgenic mice were crossed with p21 WAF1/CIP1 knockout mice to generate three groups of mice carrying the v-Ha-ras transgene, but diering in their p2l dosage (ras/ p21
). Control mice of the same background diering in their p2l functional status (p21
), but negative for the v-Ha-ras transgene, were also monitored.
Mouse genotyping
The genotypes of four-week old ospring resulting from the crosses of the p21 knockout and MMTV/v-Ha-ras transgenic mice were determined by PCR. The PCR was performed using v-Ha-ras and p21 speci®c primers and genomic DNA isolated from a *1 cm section of mouse tail by the method described in Davis et al. (1980) . For PCR, *50 ng of DNA was ampli®ed in the presence of 1.5 mM MgCl 2 , 0.2 mM dNTP mix, 16 Qiagen buer, 1 mM of each primer and 2 U of Taq polymerase (Qiagen). The sequence of the primers is the following: R-MMTV/v-Ha-ras (GGGCATAAGCACA-GATAAAAC ACT), F-MMTV/v-Ha-ras (CCCAAGGCT-TAAGTAAGTTTTTGG), p21+116F (AAGCCTTGATTC-TGATGTGGGC), p21-135 (TGACGAAGTCAAAGTTC-CACCG), and Neo-19+ (GCTATCAGGACATAGCGTT-GGC). Samples were incubated at 958C for 3 min before primer-speci®c cycling. Parameters were as follows: p21 (mutant=750 bp, wt=900 bp) (958C ± 618C ± 728C)640 cycles; v-Ha-Ras (852 bp) (958C ± 558C ± 728C)630 cycles.
Tumor development monitoring and sample collection
The female ospring were monitored weekly for tumors by observation and palpation. Tumor diameters were measured in three dimensions using calipers, and tumor volume was calculated as length 6 width 6 height. Samples of tumor and normal tissue were collected in 10% neutral buered formalin for histopathologic analysis. All surgical and experimental procedures performed on the mice were in accordance with our institution and with the NIH guidelines outlined in the`Guide for Care and Use of Laboratory Animals' (NIH publication 85 ± 23). Animals were autopsied immediately after sacri®ce, and external as well as internal organs were grossly examined. Representative tissue samples were obtained from salivary glands, mammary glands, lungs, liver, kidneys, spleen, and Harderian (lacrimal) glands. For general microscopy, tissues were embedded in paran, and 3 mm-thick sections were cut and stained with hematoxylin and eosin. Tissues were also processed using either an avidinbiotin complex method or a labeled streptavidin-biotin method after antigen retrieval. (Taylor et al., 1994) Tissues were immunostained with goat polyclonal antibodies against CD3e, 1 : 400 dilution (T cell marker), and CD20, 1 : 200 (B cell marker) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), factor VIII, 1 : 400 dilution (endothelial cell marker) (Dako, Carpinteria, CA, USA) and Ki-67 clone B56, 1 : 400 dilution (cell proliferation marker) (PharMingen, San Diego, CA, USA). Negative and positive controls included the omission of the primary antibody and normal or tumor tissues with known high marker expression. p21 WAF1/CIP1 expression was analysed by immunohistochemistry with an anti-p21 antibody (sc-397-G, Santa Cruz Biotechnology).
Mitotic figure
A determination of the number of mitotic ®gures in tumor samples was performed by counting the number of visible mitotic ®gures within cells in 10 random HPFs (6400). The total number of mitotic ®gures was determined for all 10 HPFs, as well as the percentage of tumor cells with visible mitotic ®gures within each ®eld. All mitotic counts were performed blinded with respect to the p21 genotype.
Apoptosis detection in tumor samples
In situ labeling of apoptosis-induced DNA strand breaks was carried out using the ApopTag Peroxidase In Situ Apoptosis detection kit (Intergen Company, Caschase, NY, USA). Samples were deparanized and treated with proteinase K (2 mg/ml) for 15 min. Samples were then rinsed and incubated with 50 ml of TUNEL reaction solution containing 0.3 u/ml TdT (terminal deoxynucleotide transferase), TdT buer, 0.01 nmol/ml biotin 16 dUTP, and 0.05 mg/ml BSA. Samples were incubated with 50 ml of staining solution (5% nonfat milk, 46SSC, 0.1% Triton-X-100, and 2.5 mg/ml streptavidin-FITC). The number of apoptotic cells, from normal and tumor tissues, was counted in 10 random HPFs.
Statistical analysis
The three groups of mice were compared with respect to frequencies using Fisher's Exact Test. For quantitative variables, the comparisons were done using the Kruskal Wallis Test for more than two groups. These were followed by Wilcoxon Rank Sum Tests for pairs of groups. All Pvalues were computed by exact methods using Proc Freq and Proc Npar1way of SAS (version 8).
